Biotech | April 08, 2026
Stipple Bio raises $100M Series A to advance next-gen cancer therapies
The new capital is expected to fund the company through 2029
The new capital is expected to fund the company through 2029
The collaboration promises expanded funding for Thai universities, research institutes, companies, and global research partners working in Thailand
The drug meets all primary endpoints across 608 patients in Europe and India, strengthening the company's biosimilars pipeline
Multi-year CDMO partnership combines AI-led virtual development, precision chemistry and GMP manufacturing to accelerate five high-science APIs across regulated markets
India’s first prospective study finds molecular testing improved diagnostic clarity in 50% of complex sarcoma cases
MoU to deploy Qure.ai’s chest X-ray solution across 20 government facilities aims to improve early detection in urban and rural populations
As part of the deal, Red Nucleus also gains indirect ownership of the company’s Indian arm
Samsung Biologics will continue supplying products previously manufactured at the site to GSK
Move aligns global biologics identity under the Biocon Biologics brand
Safety was equally impressive. ENV-294 was well tolerated
Subscribe To Our Newsletter & Stay Updated
